Speech-Based Monitoring of Antipsychotic Use in Schizophrenia
Tests voice interviews to monitor antipsychotic use in adults with schizophrenia.
Plain-language title generated from the registry record
Registry title: Voice-Based Biomarkers: A Novel Approach to Monitoring and Predicting Schizophrenia Relapses
Key facts
- Where
- Paris, FranceSee the 2 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 60 years old?
Source: NCT06613334, who can take part
Where in France
- Groupe Hospitalo-Universitaire Paris Psychiatrie & NeurosciencesParis, FranceNot yet recruiting
- Groupe Hospitalo-Universitaire Paris Psychiatrie et Neurosciences, ParisParis, FranceTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Centre Hospitalier St Anne
- Trial code
- NCT06613334
- Record updated
- 21 September 2026
- Original description
Schizophrenia is a serious psychiatric illness affecting approximately 25 million people worldwide. Patients with schizophrenia experience hallucinations, auditory illusions, disordered thinking, movement disorders, cognitive impairment and social isolation. Treatments with antipsychotics have proven effective in improving their living conditions, but poor compliance results in relapses and rehospitalizations for the majority of patients, which often results in a worsening of residual symptoms. The prevention of these relapses is a major issue in the care of these patients and frequent monitoring is necessary. The use of a simple, rapid and inexpensive tool to monitor symptoms and treatment effect in schizophrenia could improve the effectiveness of the treatment of these patients and prevent relapses. Speech is a good candidate as a biomarker in the monitoring of patients with schizophrenia. Schizophrenia is accompanied by speech disorders including poor speech, variations in tone or intensity or even difficulties in organizing speech.Read full original descriptionShow less
Automatic Measurement of Antipsychotic Medication Adherence in Schizophrenia Through Speech (OBSERVSPEECH)
Schizophrenia is a serious psychiatric illness affecting approximately 25 million people worldwide. Patients with schizophrenia experience hallucinations, auditory illusions, disordered thinking, movement disorders, cognitive impairment and social isolation. Treatments with antipsychotics have proven effective in improving their living conditions, but poor compliance results in relapses and rehospitalizations for the majority of patients, which often results in a worsening of residual symptoms. The prevention of these relapses is a major issue in the care of these patients and frequent monitoring is necessary. The use of a simple, rapid and inexpensive tool to monitor symptoms and treatment effect in schizophrenia could improve the effectiveness of the treatment of these patients and prevent relapses. Speech is a good candidate as a biomarker in the monitoring of patients with schizophrenia. Schizophrenia is accompanied by speech disorders including poor speech, variations in tone or intensity or even difficulties in organizing speech.
Inclusion: Affiliated to a social security or other social protection scheme; Diagnosed with schizophrenia according to the DSM-5 (code F20); Stable state without duration criteria; Main treatment with risperidone or paliperidone, aripiprazole, olanzapine in oral or long-acting injectable form; Complementary treatment with an antipsychotic for anxiolytic or sedative purposes: chlorpromazine, loxapine or cyamemazine; Able to speak and read French; Able to perform speech evaluations; Able to answer questionnaires on smartphone; May be under curatorship or guardianship; Agreeing to participate in the study and with informed consent signed by the subject, as well as by the legal representative in the case of a person under curatorship or guardianship.
Exclusion: Treatment with lithium salts; Participant in another study involving medication; Suffering from a neurological pathology: multiple sclerosis, Parkinson's disease, Huntington's disease or neurodegenerative disease; Suffering from a pathology that impairs French; Anti-epileptic treatment.